Iovance Biotherapeutics Investor Relations Material

Iovance Biotherapeutics (NASDAQ: IOVE) is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Our lead candidate, Poziotinib, is an orally administered small molecule inhibitor that targets the ABL kinase family with broad spectrum kinase inhibitory activity including sensitivity to low plasma concentrations of inhibitors.